Connection

Prabhakar Baliga to Antiviral Agents

This is a "connection" page, showing publications Prabhakar Baliga has written about Antiviral Agents.
Connection Strength

0.668
  1. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1003-9.
    View in: PubMed
    Score: 0.345
  2. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
    View in: PubMed
    Score: 0.128
  3. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation. 2010 May 27; 89(10):1218-23.
    View in: PubMed
    Score: 0.076
  4. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep; 6(3):101-9.
    View in: PubMed
    Score: 0.051
  5. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant. 2003 Nov; 18(11):2436-8.
    View in: PubMed
    Score: 0.048
  6. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.